Replies to post #35710 on Revive Therapeutics Ltd (RVVTF)

[Classic Warrior]

This is not true. As Rick, pointed out the recent endpoint that was submitted was with healthy patients, so it was unlikely that there would be statistical significance that was jaw dropping. However, prior endpoint with pcr data was very good from the first 210 that MF used it as an endpoint even though the FDA did not like the endpoint choice. Clearly, MF saw something he liked from the PCR test to try to push it through. Now, when he looks at symptom data,it will show some kind of time reduction to recover and based on other triggers, ie. glutathione recovery and 16 X NAC in strength, this is sure to have something big.

ps. I hope.

[Hattrick3]

Hey There Medicinecat,

The FDA or any DSMB isn’t in the business of being impressed by anything. Our sample is just too small to reach statistical significance with the original endpoints of hospitalizations and death even if we would have gotten to 1000 the last 290 or so what have been during the Omicron variant which wouldn’t have helped much, if at all. We haven’t seen the data for the first 210 because at that time the trial was still ongoing but their push to add PCR to the end point as a primary speaks volumes. Add all of the data from Buci’s ugly step sister NAC along with the in vitro studies for Buci show that it should work and work very well. Hindsight is always 20/20 but we would have certainly had the chance to change endpoints and go for an EUA if they would have tracked the symptoms data properly. If we have strong PCR data, symptoms reduction and as a secondary kept folks out of the hospital there will be value here, a lot more than our current market cap which I know isn’t saying much but value none the less!! GLTA